Current research

Monitoring emicizumab
The appropriate prescription and usage of the new drug emicizumab (Hemlibra®) for severe Haemophilia A patients is monitored through the Dutch Hemophilia Registry, combined with the 'VastePrik' patient log book. Annually (2021-2024) the HemoNED Foundation publishes an aggregated report (in Dutch) with numbers and trends about the use of emicizumab in the Netherlands.